JP2021515542A5 - - Google Patents

Info

Publication number
JP2021515542A5
JP2021515542A5 JP2020542297A JP2020542297A JP2021515542A5 JP 2021515542 A5 JP2021515542 A5 JP 2021515542A5 JP 2020542297 A JP2020542297 A JP 2020542297A JP 2020542297 A JP2020542297 A JP 2020542297A JP 2021515542 A5 JP2021515542 A5 JP 2021515542A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542297A
Other languages
English (en)
Japanese (ja)
Other versions
JP7419238B2 (ja
JP2021515542A (ja
Filing date
Publication date
Priority claimed from GBGB1803745.7A external-priority patent/GB201803745D0/en
Application filed filed Critical
Publication of JP2021515542A publication Critical patent/JP2021515542A/ja
Publication of JP2021515542A5 publication Critical patent/JP2021515542A5/ja
Application granted granted Critical
Publication of JP7419238B2 publication Critical patent/JP7419238B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542297A 2018-03-08 2019-03-08 Pd1結合剤 Active JP7419238B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB1803745.7 2018-03-08
GBGB1803745.7A GB201803745D0 (en) 2018-03-08 2018-03-08 PD1 binding agents
GBGB1807176.1A GB201807176D0 (en) 2018-03-08 2018-05-01 PD1 Binding agents
GB1807176.1 2018-05-01
GBGB1811302.7A GB201811302D0 (en) 2018-03-08 2018-07-10 PD1 binding agents
GB1811302.7 2018-07-10
GBGB1816372.5A GB201816372D0 (en) 2018-03-08 2018-10-08 PD1 binding agents
GB1816372.5 2018-10-08
GB1817652.9 2018-10-29
GBGB1817652.9A GB201817652D0 (en) 2018-03-08 2018-10-29 PD1 binding agents
PCT/EP2019/055901 WO2019170885A1 (en) 2018-03-08 2019-03-08 Pd1 binding agents

Publications (3)

Publication Number Publication Date
JP2021515542A JP2021515542A (ja) 2021-06-24
JP2021515542A5 true JP2021515542A5 (enExample) 2022-03-15
JP7419238B2 JP7419238B2 (ja) 2024-01-22

Family

ID=61972774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542297A Active JP7419238B2 (ja) 2018-03-08 2019-03-08 Pd1結合剤

Country Status (11)

Country Link
US (3) US10858434B2 (enExample)
EP (1) EP3762418A1 (enExample)
JP (1) JP7419238B2 (enExample)
KR (1) KR20200128544A (enExample)
CN (1) CN111819201A (enExample)
AU (1) AU2019229663A1 (enExample)
CA (1) CA3092169A1 (enExample)
GB (5) GB201803745D0 (enExample)
IL (1) IL277131A (enExample)
SG (1) SG11202008240RA (enExample)
WO (1) WO2019170885A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201914747D0 (en) * 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
BR112022025632A2 (pt) * 2020-06-23 2023-01-17 Kadmon Corp Llc Anticorpos anti-pd-1 e proteínas de fusão
WO2022258011A1 (zh) * 2021-06-11 2022-12-15 广东菲鹏制药股份有限公司 抗pd-1人源化抗体或其抗原结合片段及其应用
CN116253796A (zh) * 2022-09-21 2023-06-13 三优生物医药(上海)有限公司 靶向冠状病毒的中和抗体、其抗原结合片段及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218257A (zh) * 2005-03-25 2008-07-09 托勒克斯股份有限公司 Gitr结合分子及其用途
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) * 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
CN112552401B (zh) * 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
WO2017055404A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents

Similar Documents

Publication Publication Date Title
JP2021519100A5 (enExample)
JP2021515541A5 (enExample)
JP2021515542A5 (enExample)
JP2021513323A5 (enExample)
JP2022553908A5 (enExample)
JP2024513921A5 (enExample)
JP2021516537A5 (enExample)
FI4041763T3 (fi) Pd1:tä ja vegfr2:ta kaksoissitovia aineita
JP2017149720A5 (enExample)
JP2020514277A5 (enExample)
HRP20200583T1 (hr) Protutijela koja neutraliziraju gp120 i njihova upotreba
JP2019201643A5 (enExample)
JP2019500892A5 (enExample)
JP2019500891A5 (enExample)
JP2018506961A5 (enExample)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2016536020A5 (enExample)
JP2022533538A5 (enExample)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2021534797A5 (enExample)
JP2024540148A5 (enExample)
JP2020521504A (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
JP2020513759A5 (enExample)
JP2021515544A5 (enExample)
RU2019135404A (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний